Pharmacology Biochemistry and Behavior, Vol. 4. Copyright © 1976 by ANKHO International Inc.
All rights of reproduction in any form reserved. Printed in the U.S.A.

UNIVERSITY OF HAWAII LIBRARY

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 4, 1976

SUBJECT INDEX

- Acetylcholine
  - hypothalamic injections and heat-escape behavior, 369
  - striatal dopamine and REM deprivation, 401
  - temperature regulation, 369
- Acetylcholinesterase inhibitors
  - discrimination learning, 151
- Active avoidance
  - prenatal exposure to methyl-mercury, 385
  - stimulus locale and d-amphetamine and scopolamine, 103
  - strain differences, 103
- ACTH
  - plasma corticosterone and hypothalamic catecholamines, 95
- $ACTH_{4-9}$
  - analogue and metabolic fate, 583
- 7-d-phe $ACTH_{4-10}$
  - visual evoked responses, 273
- 7-l-phe $ACTH_{4-10}$
  - visual evoked responses, 273
- Actinomycin D (AMD)
  - hippocampal application and memory, 515
- Activity
  - restraint stress, 289
- Adrenalectomy
  - wheel running and circadian rhythms, 617
- Aggressive behavior
  - Apomorphine-induced and morphine and haloperidol and oxyperomide, 639
  - 6-OHDA, 381
  - operant behavior and chronic chlorodiazepoxide administration, 99
  - septal lesions and PCPA, 397
- Alanine
  - brain levels and avoidance behavior, 53
- C_3-Alcohol
  - selection in mice and strain differences and open field, 527
- Alpha-methyl-dopa
  - hypothalamic catecholamines and plasma corticosterone, 95
- Alpha-methyl-meta-tyrosine
  - hypothalamic catecholamines and plasma corticosterone, 95
- Alpha-methyl-para-tyrosine (AMPT)
  - apomorphine self-administration, 611
  - hypothalamic catecholamines and plasma corticosterone, 95
- Amino acid
  - brain levels and avoidance behavior, 53
  - uptake and learning, 7
- Aminooxyacetic acid
  - audiogenic seizures, 269
- Aminophylline
  - stria terminalis and eating, 107
- Amphetamine
  - amygdala lesions and taste aversion, 541
- d-Amphetamine
  - active avoidance and strain differences, 103
  - cycloheximide and memory, 305
  - food and H_2O and sucrose intake, 591
  - l-amphetamine and ^{3}H-norepinephrine brain metabolism, 545
  - learning, 239
  - operant behavior and rate-dependent effects, 73
  - passive avoidance, 703
  - puromycin and memory, 353
  - rate-dependent drug effects, 165
  - self-administration in monkeys, 45
  - self-injection and AMPT, 611
  - self-stimulation, 575
- l-Amphetamine
  - d-amphetamine and ^{3}H-norepinephrine brain metabolism, 543
  - operant behavior and rate-dependent effects, 73
  - self-administration in monkeys, 45
  - self-stimulation, 575
- Amnesia
  - cycloheximide and 6-OHDA and passive avoidance, 347
  - cycloheximide and taste aversion, 181
- Amygdala
  - lesions and taste aversion by LiCl and amphetamine, 541
  - self-stimulation and spiroperidol, 211
  - thermoregulation and prostaglandin E_1 and noradrenaline, 143
- Analgesia
  - morphine microinjection into mouse brain, 23
- Anesthesia
  - sexual behavior, 497
- Angiotensin II
  - drinking and Sar^1-Ala^8-angiotensin II, 243
  - drinking and subfornical organ lesions, 651
  - drinking and taste preference, 363
  - plasma levels and drinking, 317
- Sar^1-Ala^8-Angiotensin II
  - drinking and angiotensin II, 243
- Anisomycin
  - cerebral protein synthesis inhibition and passive avoidance, 13
- Anterior hypothalamus
  - thermoregulation and prostaglandin E_1 and noradrenaline, 143
- Apomorphine
  - epileptic seizures, 263
  - induced aggression and morphine and haloperidol and oxyperomide, 639
  - induced motor activity and harmine and brain lesions, 1
  - self-administration and AMPT, 611
  - self-stimulation, 575
  - sexual behavior, 67
  - sleep cycles, 119
- Apparatus
  - chemitrode for chemical and electrical stimulation, 621
  - chronic intravenous system, 613
  - drinking device for rhesus monkeys, 609
  - IV infusion via sagittal and transverse sinuses: apparatus, 469
  - measurement of stereotyped gnawing, 201
  - startle response apparatus, 713
  - tremor measurement, 721
  - vestibular stimulation, 657

QV
P901

Arecoline
shock avoidance, 561
Aspartate
brain levels and avoidance behavior, 53
Atropine
exploratory behavior, 695
Atropine sulfate
habituation in chicks, 235
Avoidance behavior
amino acid brain levels, 53
chlorpromazine and escape behavior, 111
chronic lead ingestion, 411
NE brainstem lesions with 6-OHDA, 343
Δ^9-tetrahydrocannabinol, 17
Audiogenic seizures
aminooxyacetic acid, 269

Benzhexol
exploratory behavior, 695
Betel quid
reaction time, 627
Blood pressure
propranolol, 283
restraint stress, 289
testosterone and sex differences, 339
Brain
amygdala, 143, 211, 541
anterior hypothalamus, 143
brainstem, 343
cerebellum, 53
cerebrum, 13
cortex, 175
diencephalon, 53
hippocampus, 143, 225, 515
hypothalamus, 95, 211, 551, 369, 647
lateral hypothalamus, 143, 575
lateral preoptic area, 651
locus coeruleus, 211, 575
medulla, 53, 601
mesencephalon, 53, 143
midbrain, 601
neocortex, 601
nucleus accumbens, 211
nucleus reuniens, 551
orbitofrontal cortex, 211
periacqueductal gray matter, 23
pons, 53, 601
preoptic area, 185
raphe nuclei, 1, 477
subfornical organ, 651
substantia nigra, 1, 551, 575
stria terminalis, 107
telencephalon, 53
third ventricle, 651
zona incerta, 551
Brain amines
epileptic seizures, 263
testosterone and ranacide, 59
Brainstem
NE lesions with OHDA and avoidance and open field behavior, 343
Brain stimulation
cannula system, 351
Butanol
sleep and strain differences, 679
t-Butanol
sleep and strain differences, 679

Cannabidiol
food and H_2O and sucrose intake, 591
Cannabinol
food and H_2O and sucrose intake, 591
Cannabis
cross tolerance and Δ^9-THC, 635
Carbachol
shock avoidance, 561
Castration
sexual behavior and l-dopa and pimozide, 521
Catecholamines
myocardial sensitivity to stress, 27, 35
Cerebellum
avoidance behavior and amino acid levels, 53
NE levels after neonatal injections of 6-OHDA, 601
Cerebrum
protein synthesis inhibition and passive avoidance, 13
Chemical stimulation
chemitrode, 621
Chloral hydrate
sleep and strain differences, 679
Chlordiazepoxide
chronic administration and aggression, 99
scheduled-induced drinking and operant behavior, 299
Chloroform
monoamine inactivation, 447
Chlorpromazine
avoidance and escape behavior, 111
heart rate and blood pressure, 111
interaction with TRF, 279
p-Chlorophenylalanine (PCPA)
predatory behavior, 217
startle response and alcohol, 311
synergistic action with LSD, 231
Circadian rhythms
adrenalectomy or dexamethasone and wheel running, 617
Citric acid
phenobarbital and intake in fluid deprivation, 335
Clonidine
sexual behavior, 67
Clonidine HCl
self-stimulation, 575
CN-69,725-27
hypothalamic injection and sexual behavior, 685
CO_2
monoamine inactivation, 447
Cocaine
self-administration, 461
self-administration and perphenazine, 427
self-administration in monkeys, 45, 207
Conditioned suppression
drug-induced, 221
prenatal exposure to methylmercury, 385
Cortex
ablations and alcohol tolerance and cycloheximide, 175
Corticosteroids
plasma levels and scotophobin, 481
Corticosterone
plasma levels and hypothalamic catecholamines, 95
plasma levels and restraint stress, 289
Cyclic AMP
striae terminalis and eating, 107
Cycloheximide
amnesia and 6-OHDA and passive avoidance, 347
cerebral protein synthesis inhibition and passive avoidance, 13
cortical ablation and alcohol tolerance, 175
d-amphetamine and memory, 305
passive avoidance, 441, 703
plasma testosterone, 185
taste aversion amnesia, 181

Dependence
injections vs implantation of morphine, 323
Dexamethasone
wheel running and circadian rhythms, 617

Dexetimide
apomorphine induced aggression, 639
Diencephalon
avoidance behavior and amino acid levels, 53
Diethyl ether
sexual behavior and anesthesia, 497
Diethylpropion
self-administration in monkeys, 45
Di-n-propylacetate
operant behavior and locomotor activity, 643
Diphenylhydantoin
sexual behavior and anesthesia, 497
Discrimination learning
acetylcholinesterase inhibitors, 151
hippocampal application of actinomycin D, 515
UMP influence on hippocampal ^{3}H-leucine incorporation, 225
Ditran
discrimination learning, 151
L-Dopa
interaction with TRF, 279
sexual behavior, 521
Dopamine
brain efflux and drinking and eating, 551
brain levels and syrosingopine, 419
epileptic seizures, 263
hypothalamic levels and plasma corticosterone, 95
NA and motor activity and reserpine or AMPT pretreatment, 661
striae terminalis and eating, 107
striatal ACh and REM deprivation, 401
testosterone and ranacide, 59
Drinking
angiotensin II and subfornical organ lesions, 651
angiotensin and taste preference, 363
angiotensin II induced and inhibition by sar^{1}-ala^{8}-angiotensin II, 243
brain dopamine efflux, 551
device for rhesus monkeys, 609
5-HT and Ro 4-4602 and operant behavior, 407
inhibition by pitressin following water deprivation, 203
plasma angiotensin II, 317
schedule induced and chlorodiazepoxide, 299
Drug
acetyl choline, 369, 401
actinomycin D (AMD), 515
C_3-alcohol, 527
alpha-methyl-dopa, 95
alpha-methyl-meta-tyrosine, 95
alpha-methyl-paratyrosine (AMPT), 95, 611
aminooxyacetic acid, 269
aminophylline, 107
amphetamine, 541
d-amphetamine, 45, 73, 103, 165, 239, 305, 353, 575, 591, 611, 703
l-amphetamine, 45, 73, 575
angiotensin II, 243, 317, 363, 651
sar^{1}-ala^{8}-angiotensin II, 243
anisomycin, 13
apomorphine, 1, 67, 119, 263, 575, 611, 639
arecoline, 561
atropine sulphate, 235, 695
benzhexol, 695
betel quid, 627
butanol, 679
t-butanol, 679
cannabis, 635
cannabinol, 591
cannabidiol, 591
carbachol, 561
chloral hydrate, 679
clonidine, 67, 575
chlorodiazepoxide, 99, 299
p-chlorophenylalanine (PCPA), 217, 231, 311, 343, 357, 397, 535, 629
chloroform, 447
chlorpromazine, 111, 279
CO_2, 447
cocaine, 45, 207, 427, 461
cyclic AMP, 107
cycloheximide, 13, 175, 181, 185, 305, 347, 441, 703
dexetimide, 639
diethyl ether, 497
diethylpropion, 45
diphenylhydantoin, 497
ditran, 151
l-dopa, 279, 521
dopamine (DA), 59, 95, 107, 263, 401, 419, 551, 661
epinephrine, 27, 35
ethanol, see alcohol, 169, 175, 239, 473, 535, 679
ether, 447
etonitazene, 137
fenfluramine, 629
genever, 239
guanethidine, 95
haloperidol, 279, 311, 639, 703
harmine, 1
heroine, 129
hexobarbital, 497
6-hydroxydopamine (6-OHDA), 343, 347, 381, 601
5-hydroxytryptamine (5-HT), 59, 263, 407, 417
2-imidazolidone-4-carboxylic acid (ICA), 689
imipramine, 671
H^{3}-inulin, 7
iproniazid, 53
isoprenaline, 703
isoproterenol, 317
lead, 411
H^{3}-leucine, 7, 225
lignocaine, 441
lithium chloride (LiCl), 541
LSD, 67, 221, 231
maleate, 703
mazidol, 207
mepyramine, 703
d-methamphetamine, 45, 629
methanol, 679
L-methionine-S-sulfoxide (MSO), 689
methoxamine, 703
3-methoxy-4-hydroxyphenylglycol (MHPG), 647
methyl atropine nitrate, 221, 235, 561
methylmercury dicyandiamide, 507
methylmercury hydroxide, 385
methylphenidate, 393, 671
methysergide, 67
α-methyltyrosine, 311
α-methyl-p-tyrosine, 661
metrazol, 123
morphine, 23, 159, 259, 323, 419, 569, 629, 639
naloxone, 159, 259, 323, 639
neostigmine, 151, 561
nicotine, 435, 561
noradrenaline (NA), 107, 143, 375, 661
l-noradrenaline bitartrate, 703
^{3}H-norepinephrine, 39
norepinephrine (NE), 27, 35, 59, 95, 263, 289, 343, 419, 601, 647
oxyperomide, 639
paraldehyde, 679
pargyline, 311
pentobarbital, 221, 417, 679, 709
pentylenetetranol, 353
phenobarbital, 335
phenoxybenzamine, 67, 311
perphenazine, 427

Drug (continued)
physostigmine, 151
picrotoxin, 497
pilocarpine, 561
pimozide, 67, 259, 311, 521, 725
piperoxane, 703
pitressin, 203
polyethelene glycol, 317
postaglandin E_1, 143
practolol, 531
propranolol, 283, 311, 531, 703
d-propranolol, 531
di-n-propylacetate, 643
psilocybin, 221
puromycin, 353
reserpine, 119, 279, 485, 661
Ro 4-4602, 407
scopolamine, 103, 255, 695
scopolamine hydrobromide, 561
scotophobin, 481
spiroperidol, 211
strychnine, 353, 497
sulpiride, 279
syrosingopine, 419
tetrabenazine, 53
Δ^9-tetrahydrocannabinol (Δ^9-THC), 17, 249, 591, 635
trichloroethanol, 679
thymoxide HCl, 575
thyrotropin releasing factor (TRF), 279
uridine-5-monophosphate (UMP), 225
viloxazine, 729
Drug synergism
LSD and p-chlorophenylalanine, 231

Eating
brain dopamine efflux, 551
heroin and feeding patterns, 129
stria terminalis and cyclic AMP
ECS
reserpine and seizure thresholds, 485
EEG
metrazol administration, 119
Electrical stimulation
chemitrode, 621
Epileptic seizures
brain amines, 263
Epinephrine
myocardial sensitivity to stress, 27, 35
Escape behavior
chlorpromazine and avoidance behavior, 111
prenatal exposure to methylmercury, 385
scopolamine, 255
Ether
monamine inactivation, 447
Ethanol
learning, 239
operant behavior, 473
operant behavior and punishment, 169
PCPA and taste aversion, 535
sleep and strain differences, 679
startle response, 311
tolerance and cortical ablation and cycloheximide, 175
Etonitazene
schedule-induced consumption, 137
Exploratory behavior
atropine and benzhexol and scopolamine, 695
MSO and ICA administration, 689
nicotine and locomotion patterns, 435
Extinction
aggression and chronic chlorodiazepoxide administration, 99

Feeding patterns
heroin, 129
Fenfluramine
pretreatment and taste aversion, 629
Fluid deprivation
pentobarbital and saccharin and citric acid intake, 335
Food intake
cannabinoids, 591
Foot shock
MSO and ICA, 689

Genever
learning, 239
Glutamate
brain levels and avoidance behavior, 53
Glycine
brain levels and avoidance behavior, 53
Gnawing
method of measuring, 201
Grooming behavior
appetitive and consumatory grooming, 329
theoretical review, 329
Guanethidine
hypothalamic catecholamines and plasma corticosterone, 95

Habituation
atropine sulfate and methylatropine nitrate administration, 235
Haloperidol
apomorphine-induced aggression, 639
interaction with TRF, 279
passive avoidance, 703
startle response and alcohol, 311
Harmine
apomorphine-induced motor activity and brain lesions, 1
Hatching
prenatal injections of methylmercury, 507
Heart rate
propanolol, 283
Heat-escape behavior
hypothalamic injections of ACh, 369
Heroin
feeding patterns, 129
Hexobarbital
sexual behavior and anesthesia, 497
Hippocampus
application of actinomycin D and memory, 515
discrimination learning, 225
NE levels after neonatal injections of 6-OHDA, 601
thermoregulation and prostaglandin E_1 and noradrenaline, 143
Hormone
ACTH, 95, 583
7-d-phe $ACTH_{4-10}$, 273
7-l-phe $ACTH_{4-10}$, 273
CN-69,725-27, 685
corticosterone, 95, 289
dexamethasone, 617
somatostatin, 455
testosterone, 185, 339
testosterone propionate, 59, 521
thyrotropin releasing hormone (TRH), 455, 709
5-HT
brain levels and syrosingopine, 419
epileptic seizures, 263
operant behavior and drinking, 407
testosterone and ranacide, 59
6-Hydroxydopamine (6-OHDA)
aggressive behavior, 381
brain NE levels after neonatal injections, 601
brainstem lesions and avoidance and open field behavior, 343
cycloheximide and amnesia and passive avoidance, 347

Hyperactivity
MHPG urine output and propranolol, 531
morphine microinjection into mouse brain, 23
practolol, 531
Hypothalamus
ACh injections and heat-escape behavior, 369
catecholamines and plasma corticosterone, 95
dopamine efflux and drinking and eating, 551
injection of CN-69,725-27 and sexual behavior, 685
NE and MHPG levels and maternal behavior, 647
self-stimulation and spiroperidol, 211
somatostatin and TRH injections and sleep and motor behavior, 455
Hypothermia
morphine dependence, 259
raphé self-stimulation, 477

ICA
MSO and operant and exploratory behavior and foot shock, 689
Imipramine
methylphenidate and operant behavior, 671
Immobility reflex
neuropharmacological studies, 85
theoretical review, 85
Infant behavior
following Δ^9THC to pregnant mothers, 249
^{3}H-Inulin
uptake and learning, 7
Iproniazid
avoidance behavior and brain amino acid levels, 53
Isoprenaline
passive avoidance, 703
Isoproterenol
drinking and plasma angiotensin II, 317

Lateral hypothalamus (LH)
self-stimulation and catecholamines, 575
thermoregulation and prostaglandin E_1 and noradrenaline, 143
Lateral preoptic area
drinking and angiotensin II, 651
Lead
chronic ingestion and behavioral effects, 411
Learning
amino acid uptake, 7
d-amphetamine, alcohol and genever, 239
prenatal injections of methylmercury, 507
^{3}H-Leucine
discrimination learning, 225
uptake and learning, 7
LiCl
amygdala lesions and taste aversion, 541
Lignocaine
passive avoidance, 441
Locomotion patterns
nicotine and exploratory behavior, 435
Locomotor activity
di-n-propylacetate and operant behavior, 643
methylphenidate, 393
Locus coeruleus
self-stimulation and catecholamines, 575
self-stimulation and spiroperidol, 211
LSD
conditioned suppression, 221
sexual behavior, 67
synergistic action with p-chlorophenylalanine, 231

Maleate
passive avoidance, 703
Maternal behavior
hypothalamic NE and MHPG, 647
Mazindol
self-administration in monkeys, 207
Medulla
avoidance behavior and amino acid levels, 53
NE levels after neonatal injections of 6-OHDA, 601
Memory
cycloheximide and d-amphetamine, 305
hippocampal application of actinomycin D, 515
passive avoidance and puromycin, 353
method to study in goldfish, 489
Mepyramine
passive avoidance, 703
Mesencephalon
avoidance behavior and amino acid levels, 53
thermoregulation and prostaglandin E_1 and noradrenaline, 143
Methamphetamine
pretreatment and taste aversion, 629
d-methamphetamine
self-administration in monkeys, 45
Methanol
sleep and strain differences, 679
Method
cannula system for local brain stimulation, 351
method to study goldfish short-term memory, 489
Methoxamine
passive avoidance, 703
3-Methoxy-4-hydroxyphenylglycol (MHPG)
urine output and hyperactivity and propranolol, 531
Methyl atropine
shock avoidance, 561
Methyl atropine nitrate
conditioned suppression, 221
habituation in chicks, 235
Methylmercury
prenatal exposure and behavioral effects, 385
Methylmercury dicyandiamide
prenatal injection and hatching and learning, 507
Methylphenidate
imipramine and operant behavior, 671
locomotor activity, 393
α-Methyl-p-tyrosine (AMPT)
reserpine pretreatment and motor activity and DA and NA, 661
α-Methyltyrosine
startle response and alcohol, 311
Methysergide
sexual behavior, 67
Metrazol
retention and EEG, 119
MHPG
NE hypothalamic levels and maternal behavior, 647
Midbrain
NE levels after neonatal injections of 6-OHDA, 601
Monoamines
inactivation and ether and chloroform and CO_2, 447
Morphine
analgesia and brain catecholamines, 419
apomorphine-induced aggression, 639
dependence and operant behavior, 569
dependence and thermoregulation, 259
injection vs implantation and withdrawal, 232
periacqueductal grey and analgesia and hyperactivity, 23
pretreatment and taste aversion, 629
taste aversion and naloxone, 159
Motor activity
apomorphine-induced and harmine and brain lesions, 1
restoration in reserpine or AMPT pretreatment and DA and NA, 661
Motor behavior
somatostatin and TRH hypothalamic injections and sleep, 455
MSO
ICA and operant and exploratory behavior and foot shock, 689
Myocardium
sensitivity to catecholamines and stress, 27, 35
stress and ^{3}H-norepinephrine uptake, 39

Naloxone
apomorphine-induced aggression, 639
injections vs implantation of morphine, 323
morphine dependence and thermoregulation, 259
taste aversion and morphine, 159
Narcosis
pentobarbital and TRH, 709
Neocortex
NE levels after neonatal injections of 6-OHDA, 601
Neostigmine
discrimination learning, 151
shock avoidance, 561
Nicotine
exploratory behavior and locomotion patterns, 435
shock avoidance, 561
Noise
viloxazine and open field behavior, 729
Noradrenaline
brain injections and thermoregulation, 143
DA and motor activity and reserpine or AMPT pretreatment, 661
self-stimulation, 375
striae terminalis and eating, 107
1-Noradrenaline bitartrate
passive avoidance, 703
Norepinephrine
brain levels after neonatal injections of 6-OHDA, 601
brain levels and syrosingopine, 419
brain levels following restraint stress, 289
brainstem lesions with 6-OHDA and avoidance and open field behavior, 343
epileptic seizures, 263
hypothalamic levels and plasma corticosterone, 95
MHPG hypothalamic levels and maternal behavior, 647
myocardial sensitivity to stress, 27, 35
testosterone and ranacide, 59
^{3}H-Norepinephrine
brain metabolism and d- and l-amphetamine, 545
myocardial uptake during stress, 39
Nucleus accumbens
self-stimulation and spiroperidol, 211
Nucleus reuniens
dopamine efflux and drinking and eating, 551

Open field behavior
C_3-alcohol selection and strain differences in mice, 527
chronic lead ingestion, 411
MHPG urine output and propranolol, 531
NE brainstem lesions with 6-OHDA, 343
neonatal injection of 6-OHDA, 601
noise and Viloxazine, 729
practolol, 531
prenatal exposure to methylmercury, 385
Operant behavior
aggression and chronic chlordiazepoxide administration, 99
alcohol and punishment, 169
brain dopamine efflux and drinking and eating, 551
di-n-propylacetate and locomotor activity, 643
effects of chlordiazepoxide, 299
ethanol, 473
free operant avoidance schedule and chlorpromazine, 111
5-HT and Ro 4-4602 and drinking, 407
imipramine and phenylphenidate, 671
morphine dependence, 569
MSO and ICA administration, 689
rate-dependent drug effects and d-amphetamine, 165
rate-dependent effects of drugs, 73
perphenazine and self-administration and cocaine and pentobarbital, 427
self-administration of stimulant drugs, 45
Orbitofrontal cortex
self-stimulation and spiroperidol, 211

Oxyperomide
apomorphine-induced aggression, 639

Paraldehyde
sleep and strain differences, 679
Pargyline
startle response and alcohol, 311
Passive avoidance
amnesia and cycloheximide and 6-OHDA, 347
cerebral protein synthesis inhibition by cycloheximide and anisomycin, 13
cycloheximide, 441
neonatal injections of 6-OHDA, 601
puromycin and memory, 353
sympathomimetic drugs, 703
Δ^9-THC administration to pregnant rats and pup behavior, 249
PCPA
NE brainstem lesions and avoidance and open field behavior, 343
pretreatment and taste aversion, 629
septal lesion and aggressive behavior, 397
sexual behavior, 357
taste aversion and alcohol, 535
Pentobarbital
conditioned suppression, 221
narcosis and TRH, 709
self-administration and perphenazine, 427
sleep and strain differences, 679
Pentylenetetrazol
puromycin and memory, 353
Performance
propranolol in humans, 283
Periacqueductal gray matter
morphine and analgesia and hyperactivity, 23
Perphenazine
self-administration of cocaine and pentobarbital, 427
Phenobarbital
saccharin and citric acid intake in fluid deprivation, 335
Phenoxybenzamine
sexual behavior, 67
startle response and alcohol, 311
Physostigmine
discrimination learning, 151
Pilocarpine
shock avoidance, 561
Picrotoxin
sexual behavior and anesthesia, 497
Pimozide
deprivation-induced water intake, 725
morphine dependence and thermoregulation, 259
sexual behavior, 67, 521
startle response and alcohol, 311
Piperoxane
passive avoidance, 703
Pitressin
inhibition of drinking following water deprivation, 203
Placental transfer
Δ^9-THC administration, 249
Polyethylene glycol
drinking and plasma angiotensin II, 317
Pons
avoidance behavior and amino acid levels, 53
NE levels after neonatal injections of 6-OHDA, 601
Practolol
MHPG urine output and hyperactivity, 531
Predatory behavior
p-chlorophenylalanine, 217
Prenatal injections
methylmercury and hatching and learning, 507
Preoptic area
cycloheximide injections and sexual behavior, 185
Propranolol
heart rate and blood pressure and performance in humans, 283

MHPG urine output and hyperactivity, 531
passive avoidance, 703
startle response and alcohol, 311
d-Propranolol
MHPG urine output and hyperactivity, 531
Prostanglandin E_1
brain injection and thermoregulation, 143
Protein synthesis
cerebral inhibition and passive avoidance, 13
Psilocybin
conditioned suppression, 221
Punishment
operant behavior and alcohol, 169
prenatal exposure to methylmercury, 385
Puromycin
passive avoidance and memory, 353

Ranacide
testosterone and brain amines, 59
Raphé nuclei
lesions and apomorphine-induced motor acitivity, 1
self-stimulation and hyperthermia, 477
Rate-dependent effects of drugs
theoretical review, 73
Reaction time
betel quid, 627
REM deprivation
striatal ACh and dopamine, 401
Reserpine
ECS and seizure thresholds, 485
interaction with TRF, 279
pretreatment with AMPT and motor activity and DA and NA, 661
sleep cycles, 119
Retention
metrazol administration, 119
Ro 4-4602
operant behavior and drinking, 407

Saccharin
phenobarbital and intake in fluid deprivation, 335
Schedule-induced behaviors
effects of chlorodiazepoxide on drinking, 299
etonitazene consumption, 137
Scopolamine
active avoidance and strain differences, 103
escape behavior, 255
exploratory behavior, 695
Scopolamine hydrobromide
shock avoidance, 561
Scotophobin
plasma corticosteroids, 481
Seizure
reserpine and ECS, 485
Self-administration
apomorphine and effect of AMPT, 611
apparatus, 613
cocaine, 461
cocaine and mazidol in monkeys, 207
cocaine and pentobarbital and effect of perphenazine, 427
drinking device for rhesus monkeys, 609
stimulant drugs, 45
Self-stimulation
apomorphine, 575
clonidine HCl, 575
d-amphetamine, 575
intracranial and spiroperidol, 211
l-amphetamine, 575
noradrenaline, 375
raphé and hyperthermia, 477
thymoxamine HCl, 575

Septum
lesions and PCPA and aggressive behavior, 397
Sex differences
testosterone and blood pressure, 339
Sexual behavior
anesthesia, 497
cycloheximide preoptic area injections and plasma corticosterone, 185
hypothalamic injection of CN-69,725-27, 685
L-dopa and pimozide administration after castration, 521
PCPA, 357
role of monoamines, 67
Shock avoidance
arecoline, 561
carbachol, 561
neostigmine, 561
nicotine, 561
methyl atropine, 561
pilocarpine, 561
scopolamine hydrobromide, 561
Sleep
alcohols and hypnotics and strain differences, 679
somatostatin and TRH hypothalamic injections and motor behavior, 455
Sleep cycles
apomorphine and reserpine administration, 119
Somatostatin
hypothalamic injections and sleep and motor behavior, 455
Spiroperidol
brain self-stimulation, 211
Startle response
apparatus, 713
effect of alcohol, 311
Stereotyped behavior
gnawing, method of measuring, 201
Steroid
plasma levels under stress and myocardial sensitivity, 27, 35
Stimulus locale
strain differences and active avoidance, 103
Strain differences
active avoidance and d-amphetamine and scopolamine, 103
alcohols and hypnotics, 679
C_3-alcohol selection in mice, 527
restraint stress, 289
Stress
by restraint and physiological and biochemical changes, 289
catecholamines and myocardial sensitivity, 27, 35
myocardial ^{3}H-norepinephrine uptake, 39
Striae terminalis
cyclic AMP and eating, 107
Striatum
REM deprivation and striatal ACh and dopamine, 401
Strychnine
puromycin and memory, 353
sexual behavior and anesthesia, 497
Subfornical organ
lesions and angiotensin II, 651
Substantia nigra
dopamine efflux and drinking and eating, 551
lesions and apomorphine-induced motor activity, 1
self-stimulation and catecholamines, 575
Sucrose
intake and cannabinoids, 591
Sulpiride
interaction with TRF, 279
Syrosingopine
brain catecholamines and morphine analgesia, 419

Taste aversion
amygdala lesions and LiCl and amphetamine, 541
cycloheximide and amnesia, 181
drug pretreatment, 629

morphine and naloxone, 159
PCPA and alcohol, 535
Taste preference
angiotensin II and drinking, 363
Telencephalon
avoidance behavior and amino acid levels, 53
Temperature
restraint stress, 289
Teratogenesis
theoretical review, 191
Teratogens
theoretical review, 191
Testosterone
blood pressure and sex differences, 339
plasma levels and cycloheximide, 185
ranacide and brain amine, 59
sexual behavior and l-dopa and pimozide, 521
Tetrabenazine
avoidance behavior and brain amino acid levels, 53
Δ^9-THC
administration to pregnant rats and placental transfer and pup behavior, 249
avoidance behavior, 17
cross-tolerance and cannabis, 635
food and H_2O and sucrose intake, 591
Thermoregulation
brain injections of prostaglandin E_1 and noradrenaline, 143
hypothalamic ACh injections and heat-escape behavior, 369
morphine dependence, 259
Third ventricle
angiotensin II and drinking, 651
Thymoxamine HCl
self-stimulation, 575
Thyrotropin-releasing factor (TRF)
interaction with antipsychotic drugs, 279
Tolerance
cross between cannabis and Δ^9-THC, 635
Tremors
apparatus for measuring, 721
TRH
hypothalamic injections and sleep and motor behavior, 455
narcosis and pentobarbital, 709
Trichloroethanol
sleep and strain differences, 679

Uridine-5-monophosphate
discrimination learning, 225

Viloxazine
noise and open field behavior, 729
Visual discrimination
chronic lead ingestion, 411
Visual evoked responses
7-d-phe $ACTH_{4-10}$ and 7-l-phe $ACTH_{4-10}$, 273

Water deprivation
intake and pimozide, 725
pitression inhibition of drinking, 203
plasma angiotensin II, 317
Water intake
cannabinoids, 591
deprivation and pimozide, 725
Wheel running
adrenalectomy or dexamethasone and circadian rhythms, 617
Withdrawal
injections vs implantation of morphine, 323

Zona incerta
dopamine efflux and drinking and eating, 551

AUTHOR INDEX

ABDELAAL, A. E., 317
ABRAHAM, S. F., 243, 363
ADLER, J. E., 347
ADLER, M. W., 323
ALBELDA, S. M., 185
ANISMAN, H., 103, 721
ANNAU, Z., 385
APPEL, J. B., 221, 407
APRISON, M. H., 53
ARY, M., 259

BACOTTI, A. V., 299
BALSTER, R. L., 45, 569
BARCHAS, J. D., 397
BARRETT, J. E., 169, 299
BASSETT, J. R., 27, 35, 39
BÄTTIG, K., 435
BAXTER, B. L., 611
BEAKEY, W., 255
BENEŠOVÁ, O., 119
BERNARD, B. K., 59
BILLIET, M., 239
BLACKMAN, D. E., 73
BLANK, D. L., 485
BONESE, K., 45, 427
BREESE, G. R., 709
BRESLER, D. E., 343
BREWSTER, J. M., 461
BRICK, J., 311
BROWN, C. P., 235
BUGGY, J., 651
BURTON, M. J., 211

CAGAN, M., 311
CAIRNCROSS, K. D., 27, 35, 39
CAMERON, O. G., 221
CAPPELL, H., 541
CARLISLE, H. J., 369
CARLSON, R. H., 393
CARRER, H., 497
CARTER, R. B., 407
CERLETTI, C., 323
CHEMERINSKI, E., 239
CLARKE, C. R., 617
CONTRERA, J. F., 381
COX, B., 259, 263
COX, T., 729
COYLE, I., 191
CRAWLEY, J. N., 381
CRISWELL, H. E., 23
CROWLEY, W. R., 67

D'AQUILA, R., 469
DAVIS, H. P., 13
DAVIS, M., 469, 713
DEITRICH, R. A., 679
DENTON, D. A., 243, 363
DE WIED, D., 273

DIAZ, J., 343
DOLPHIN, A. C., 661
DRISCOLL, J. W., 411
DRISCOLL, P., 435

EICHELMAN, B., 397
ELLISON, G., 343
ERICKSON, C. K., 621
ERWIN, V. G., 679

FABIAN, H. E. M., 239
FAZEL, A., 249
FEDER, H. H., 67
FEIGLEY, D. A., 255
FELDMAN, J. M., 447
FILE, S. E., 695
FISCHMAN, M. W., 111
FISH, I., 689
FISHER, A. E., 651
FLEXNER, L. B., 347
FORD, R. D., 569
FRANKLIN, K. B. J., 575
FRIED, P. A., 635
FRIESEN, H., 455
FULLER, J. L., 269
FUNK, K., 1
FURUKAWA, T., 419

GHOSH, P. K., 401
GIANUTSOS, G., 639
GIBBS, M. E., 181, 305, 441, 703
GINTON, A., 357
GLOWA, J. R., 169
GLUCKMAN, M. I., 611
GOLDBORT, R., 527
GOLDSTEIN, J. M., 613
GOUDIE, A. J., 629
GOWDEY, C. W., 129
GRUPP, L. A., 541, 725

HALARIS, A., 647
HALL, M. E., 353
HAVLICEK, V., 455
HENNINGFIELD, J. E., 473, 609
HERBERG, L. J., 107, 575
HESTON, W. D. W., 679
HINGTGEN, J. N., 53
HIRST, M., 129
HOUSER, V. P., 561
HRDINA, P. D., 401
HUGHES, J. A., 385, 507

JACOBOWITZ, D. M., 477
JACOBS, B. L., 231
JAFFE, L. S., 311
JÄRBE, T. U. C., 151
JARVIK, M. E., 461
JELLETT, L. B., 283

JENNER, P., 661
JOHANSON, C. E., 45, 427
JOHANSSON, J. O., 151
JOHNSON, C. A., 461
JOLICOEUR, F. B., 335
JONES, A. B., 397

KALANT, H., 175
KANDEL, D. A., 427
KAPLAN, L. J., 185
KEIM, K. L., 95, 289
KEINATH, S. H., 323
KIRK, J., 283
KLEMM, W. R., 85
KNOBLOCH, L. C., 591
KOGA, M., 419
KOHNO, Y., 419
KOLASIEWICZ, W., 201
KOSTRZEWA, R. M., 601
KOVACS, D. A., 621
KRAEMER, G. W., 709
KSIR, C., 165
KURTZ, P., 123
KUTSCHER, C. L., 203, 339

LAL, H., 639
LANDAUER, A. A., 283
LAUDENSLAGER, M. L., 369
LAVENHAR, S. R., 351
LEANDER, J. D., 137
LEBLANC, A. E., 175
LEE, J., 729
LEIDAHL, L., 647
LEWIS, J. K., 709
LING, G. M., 401
LINSEMAN, M. A., 541
LOIZZO, A., 279
LOMAX, P., 259, 263
LONGO, V. G., 279
LUTTGE, W. G., 685

MCBRIDE, W. J., 53
MCCARTY, R. C., 217
MCCLEARN, G. E., 679
MCGILL, T. E., 185
MCKINLEY, M. J., 243
MCKINNEY, W. T., JR., 709
MCLEAN, J. H., 601
MCMILLAN, D. E., 137

MALIN, D. H., 481
MALMNÄS, C. O., 521
MANDEL, P., 643
MANNING, F. J., 17
MARSDEN, C. D., 661
MARTIN, G. E., 551
MATSUNAGA, M., 175
MATTHIES, H., 225, 515

MAY, J. G., 601
MEISCH, R. A., 473, 609
MERCER, P. F., 317
MERLO, A. B., 239
MEYERSON, B. J., 497
MILIARESSIS, E., 477
MISSLIN, R., 643
MOBERG, G. P., 617
MOGENSON, G. J., 317
MOLTZ, H., 647
MOORE, M. S., 99
MORA, F., 211, 279
MORIN, L. P., 67
MORRISON, H., 709
MUELLER, R., 709
MYERS, R. D., 551

NAGASAKI, N., 419

OSTERMAN, D. M., 481
OTT, T., 515

PALANKER, A. L., 351
PALFAI, T., 123
PARKER, L. F., 535
PAWLOWSKI, L., 1
PETERS, R. I., 7
PETERSON, D. W., 545
PILCHER, C. W. T., 159
POHLE, W., 225
POHORECKY, L. A., 311
PRANGE, A. J., 709
PRATT, P., 627

QUADAGNO, D. M., 185

RADCLIFFE, G. J., JR., 481
RADOW, B. L., 535
RAINBOW, T. C., 347
RANDT, C. T., 689
RATWITCH, A. B., 249
REIDENBERG, M. M., 323
REMINGTON, G., 721
REZEK, M., 455
ROCHE, J. M., 447
ROLLS, E. T., 211, 375
RONDEAU, D. B., 335
ROPARTZ, P., 643
ROSENBERG, P., 647
ROSENTHAL, E., 507
RYBACK, R. S., 489

SAMUELS, S., 689
SANGER, D. J., 73
SANO, T., 419
SAYNISCH, M. J., 255
SCERNI, R. A., 611
SCHLATTER, J., 435
SCHLESINGER, K., 353
SCHMALBACH, N. L., 203, 339
SCHNEIDER, C. W., 527
SCHREIBER, H. L., 393
SCHUSTER, C. R., 111, 207
SHAW, S. G., 211, 375
SIEGEL, R. K., 461
SIGG, E. B., 95, 289
SINGER, G., 191
SIPORIN, S., 269
SMITH, R. C., 111
SOFIA, R. D., 591
SPANIS, C. W., 13
SPARBER, S. B., 507, 545
SPEISER, Z., 531
SQUIRE, L. R., 13
STAMM, E., 353
STANES, M. D., 441
STEGNER, S. E., 411
STEPHENS, D. N., 107, 575
STOLERMAN, I. P., 159
STRANGE, A. W., 527
STRICHERZ, M. E., 627

THOMPSON, D. M., 99, 671
THORNHILL, J. A., 129
THORNTON, E. W., 629
TOMOSKY, T. K., 217
TRULSON, M. E., 231, 329
TUCKER, A. R., 181, 441
TYCHSEN, R. L., 99

USTER, H. J., 435

VARDARIS, R. M., 249
VEALE, W. L., 143
VERHOEF, J., 583

WAYNER, E., 335
WAYNER, M. J., 191, 335
WEINSTOCK, M., 531
WEISINGER, R. S., 243, 363
WEISS, G. T., 713
WEISZ, D. J., 249
WESTERMANN, K. H., 1
WETZEL, W., 515
WHEELER, T. J., 629
WHISHAW, I. Q., 143
WHITESIDES, G. H., 217
WILSON, M. C., 207
WITTER, A., 583
WOLFARTH, S., 201
WOLTHUIS, O. L., 273
WOOD, W. G., 393

ZOLL, J. G., 621